May 10, 2017 12:15 PM EDT
People
Financing

From Bio­gen’s buy side to biotech CEO: Josh Man­del-Brehm joins the Po­laris fam­i­ly as a se­r­i­al en­tre­pre­neur in the mak­ing

John Carroll

Editor & Founder

Last Fri­day, Josh Man­del-Brehm wrapped a 4-year stint at Bio­gen, clos­ing out a chap­ter of his life that end­ed with a run as head of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times